Loading stock data…
Humana Inc. (HUM)
$388.90+5.06 (+1.32%)
Market ClosedLast close Jun 29
Humana Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Humana Inc. in the Healthcare sector is trading at $388.90 with a market capitalization of $39.3B. Wall Street consensus targets $304.33 (24 analysts), implying a -21.7% move over the next 12 months. The stock is currently near its 52-week high of $389.99, remaining 56.0% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -21.7% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $39.65B↑ | $32.52B↓ | $32.65B↑ | $32.39B↑ | $32.11B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $1.79B↑ | -$865.00M↓ | $302.00M↓ | $898.00M↓ | $1.85B |
| Net Income | $1.19B↑ | -$796.00M↓ | $195.00M↓ | $545.00M↓ | $1.24B |
Peer Comparison
JNJUNHPFE
Fundamentals
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, inclu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$39.32B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
34.96
Beta
Defensive asset. Lower volatility than the S&P 500.
0.68
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.92%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.08%
Volume
Today's trading volume
1.03M
Recent News
Can Carelon Drive Elevance Health's Future Earnings Growth?
Carelon is becoming a major growth driver for ELV, boosting revenues, care efficiency and long-term earnings potential despite near-term investment pressure.
Health Insurance Providers Stocks Q1 Results: Benchmarking Humana (NYSE:HUM)
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the health insurance providers industry, including Humana (NYSE:HUM) and its peers.
Illinois HealthChoice Medicaid Win Could Be A Game Changer For Humana’s (HUM) Margin Story
In June 2026, the Illinois Department of Healthcare and Family Services selected Humana Inc. to serve members statewide in HealthChoice Illinois, the state’s Medicaid managed care program covering 102 counties, with Humana’s HealthChoice plan expected to begin operations in January 2027. At the same time, investors are weighing this new Medicaid opportunity against concerns raised by a preliminary 2027 Medicare Advantage rate update and Humana’s own ambitious membership growth expectations...
Humana (HUM) Joins Illinois Medicaid Program With HealthChoice Launch Set For 2027
Humana has been selected to join Illinois' statewide Medicaid managed care program, HealthChoice Illinois. Following this selection, the company plans to launch its HealthChoice Illinois offering in January 2027, expanding its Medicaid presence in the state. Humana (NYSE:HUM) is adding a new chapter to its government program footprint with its entry into HealthChoice Illinois, a statewide Medicaid managed care program. The stock recently closed at $361.64, with returns of 17.4% over the...
Can Humana's Margin Recovery Drive Long-Term Earnings Growth?
HUM is shifting from membership growth to profitability, with lower medical costs, rising CenterWell revenues, and a margin recovery plan through 2028.